Relay Therapeutics CFO Thomas Catinazzo Sells Shares

What Happened
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (RLAY), sold 1,459 shares on July 28, 2026, at $18.61 per share for proceeds of approximately $27,152. The filing reports this sale was made to satisfy income tax withholding tied to the vesting of restricted stock units (RSUs).

Key Details

• Transaction date and type: July 28, 2026 — open-market sale (Code S) of 1,459 shares at $18.61.
• Total proceeds: about $27,152.
• Reason (footnote F1): Sale was to cover the reporting person's income tax withholding obligations upon vesting of 3,269 RSUs on July 27, 2026; the reporting person had no discretion in the sale and it complied with the issuer's RSU vesting policies.
• Ownership note (footnote F2): Filing indicates inclusion of 6,538 shares underlying RSUs. The filing excerpt does not provide a separate total shares-owned-after number beyond this note.
• Filing timeliness: Form 4 filed July 30, 2026 (two business days after the transaction), consistent with standard prompt reporting.

Context
This was a routine, tax-withholding sale tied to RSU vesting rather than a discretionary liquidation for investment purposes. Such sales are common following equity vesting and do not necessarily indicate the insider's view on the company's prospects. Purchases generally carry more weight as a bullish signal than routine withholding sales.